After US-based Moderna, Inc. released the interim data from late-stage trials that showed its vaccine candidate was 94.5 per cent efficacious against the Sars-CoV-2 virus, the ball has been set rolling in India. While players like Hyderabad-based Indian Immunologicals (IIL) say they are open to a manufacturing collaboration with Moderna, the Indian government, too, has opened dialogue with the firm.
India may also directly purchase the vaccine from Moderna and distribute here, claimed sources. “The US government has invested in research and development (R&D) as well as committed procurement of the vaccine once ready. It will have a say when